Dermata Therapeutics, Inc. — Director's Dealing 2021

Aug 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Dermata Therapeutics, Inc. (DRMA)
CIK: 0001853816
Period of Report: 2021-08-17

Reporting Person: Bedoya-Toro Munera Maria E (Senior Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-17	Common Stock	C	9162	—	Acquired	28674	Indirect
2021-08-17	Common Stock	C	19512	—	Acquired	48186	Indirect
2021-08-17	Common Stock	C	4878	—	Acquired	53064	Indirect
2021-08-17	Common Stock	C	17421	—	Acquired	70485	Indirect
2021-08-17	Common Stock	C	13658	—	Acquired	84143	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-17	Series 1d Preferred Stock	$	C	61821	Disposed		Common Stock (9162)	Indirect
2021-08-17	Series 1a Preferred Stock	$	C	400000	Disposed		Common Stock (19512)	Indirect
2021-08-17	Series 1b Preferred Stock	$	C	100000	Disposed		Common Stock (4878)	Indirect
2021-08-17	Series 1c Preferred Stock	$	C	357142	Disposed		Common Stock (17421)	Indirect
2021-08-17	Series 1 Preferred Stock	$	C	280000	Disposed		Common Stock (13658)	Indirect
2021-08-17	Series 1a Warrants	$	C	100000	Disposed	2026-03-14	Common Stock (4878)	Indirect
2021-08-17	Warrant to Purchase Common Stock	$20.50	C	4878	Acquired	2026-03-14	Common Stock (4878)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	30487	Direct

Footnotes

F1: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.

F2: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date.

F3: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date.

F4: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date.

F5: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date.

F6: The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO.

F7: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.